poisar

Stocks · News reference

Globus Medical Receives CE Mark For Its Excelsius3D Imaging System For Commercial Sale In EU, U.K.

Benzinga Newsdesk

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that the Excelsius3D™ intelligent 3-in-1 imaging system is now CE marked for commercial sale in the European Union and the

Read original sourceMore stocks news

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GMED
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

    Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

    Read original at zacks-investment-research
    CORGMEDVCYTWST
  2. Na

    Here's Why Investors Should Stay Neutral on TDOC Stock for Now

    Teladoc Health (TDOC) is positioned for growth through chronic care expansion, international presence, and its upcoming Teladoc One platform, with the stock trading at a valuation discount. However, the company faces headwinds from declining BetterHelp revenues, intense virtual care competition, and persistent unprofitability with a $16.5 billion accumulated deficit.

    Read original at zacks-investment-research
    TDOCBTSGBTSGUGMEDCNC
  3. Na

    TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

    Thermo Fisher Scientific unveiled the EMPAD G2 detector, enabling faster 4D STEM materials analysis at 10,000 frames per second with atomic-scale characterization. The detector integrates with Velox software for simplified analysis. The global 4D STEM market is projected to grow from $68 million in 2024 to $110 million by 2031 at a 6.6% CAGR, supporting TMO's growth prospects in analytical instruments.

    Read original at zacks-investment-research
    TMOGMEDVCYTILMN